Baudax Bio, Inc. Common Stock
BXRX
BXRX: Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.
moreShow BXRX Financials
Recent trades of BXRX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BXRX's directors and management
Government lobbying spending instances
-
$30,000 Jan 20, 2023 Issue: Health Issues
-
$50,000 Oct 20, 2022 Issue: Health Issues
-
$60,000 Jul 20, 2022 Issue: Health Issues
-
$60,000 Jan 20, 2022 Issue: HEALTH ISSUES
-
$60,000 Oct 20, 2021 Issue: HEALTH ISSUES
-
$60,000 Jul 21, 2021 Issue: HEALTH ISSUES
-
$60,000 Apr 20, 2021 Issue: Health Issues
-
$60,000 Jan 21, 2021 Issue: Health Issues
-
$60,000 Oct 20, 2020 Issue: Health Issues
-
$60,000 Jul 20, 2020 Issue: Health Issues
-
$60,000 Apr 26, 2020 Issue: Health Issues
-
$60,000 Jan 21, 2020 Issue: Health Issues
-
$60,000 Oct 21, 2019 Issue: Health Issues
-
$60,000 Jul 22, 2019 Issue: Health Issues
-
$60,000 May 22, 2019 Issue: Health Issues
New patents grants
-
Patent Title: Methods of administering intravenous meloxicam in a bolus dose Oct. 04, 2022
-
Patent Title: Method of treating pain in elderly patients with mild renal impairment Jan. 05, 2021
-
Patent Title: Nanoparticulate meloxicam formulations Jul. 14, 2020
-
Patent Title: Intranasal dexmedetomidine compositions and methods of use thereof Jun. 16, 2020
Federal grants, loans, and purchases
Followers on BXRX's company Twitter account
Number of mentions of BXRX in WallStreetBets Daily Discussion
Recent insights relating to BXRX
Recent picks made for BXRX stock on CNBC
ETFs with the largest estimated holdings in BXRX
Flights by private jets registered to BXRX